Akeso Biomedical™ Files TYPLEX™ Chelate Dossier to Reduce Campylobacter in EU Poultry
Akeso Biomedical, Inc., announced today that the company has filed a dossier with the European Commission to market TYPLEXTM Chelate as a zootechnical feed additive for all avian species. Akeso Biomedical is a privately held company developing novel, non-antibiotic feed additive technologies to improve food safety and animal health. Akeso’s feed additives inhibit colonization of animal hosts by bacterial pathogens, decreasing the risk of foodborne illnesses, and improving animal performance and value on the farm.
TYPLEXTM Chelate (ferric tyrosine) is Akeso’s first commercial product based on its Fe3C technology. Akeso has shown that TYPLEXTM Chelate reduces the ability of pathogenic bacteria, such as Campylobacter jejuni , Salmonella spp. , E. coli and Clostridium perfringens, to adhere to the intestinal lining of birds. Since the bacteria cannot attach, they are eliminated by gut peristalsis. The consequent reduction in gut populations of undesirable microorganisms allows birds to devote more energy to healthy growth rather than fighting off harmful bacteria.
The company has conducted extensive trials in the EU, both in laboratory scenarios and in commercial trials with Banham Poultry Ltd, to demonstrate that use in broiler feeds results in improved weight gain and feed conversion. The Fe3C technology was discovered at the University of Nottingham by Dr. Mahdavi, Professor Soultanas, and Professor Ala’Aldeen.
Simon Williams, CEO of Akeso Biomedical, said, “We are very excited to bring TYPLEXTM Chelate to the European market, and we are receiving substantial interest from poultry producers. Not only does TYPLEXTM Chelate improve poultry health and performance, but the significant reductions in carriage of Campylobacter jejuni are likely to make a significant contribution to control of human campylobacteriosis, which is the most common cause of food poisoning in the EU and elsewhere.”
Sarah Foulger, Managing Director of Banham Poultry Ltd in the UK, said, “We have been working hard with Akeso to support the development of TYPLEXTM Chelate by facilitating exclusive commercial trials, and we are eager to begin using TYPLEXTM Chelate in our broiler production.”
About Akeso Biomedical, Inc.
Akeso Biomedical, Inc. is an animal health and food safety company developing new solutions to improve animal welfare and performance and to prevent foodborne illnesses. Akeso uses a proprietary broad-spectrum iron chelate chemistry known as Fe3C. The Company’s product pipeline includes Fe3C feed additives designed to improve intestinal health and nutrient absorption in food animals, by reducing carriage of enteropathogens, including Salmonella, Campylobacter, Clostridium, and E. coli, among others. For more information please send inquiries to email@example.com .
Akeso Biomedical, Inc. is a VIC Technology Venture Development™ portfolio company.
Akeso Biomedical, Inc.
Jerome Meier, 860-833-3858
Chief Operating Officer
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Business Wire
EXCLUSIVE-GROUP19.10.2017 10:02 | pressemeddelelse
Exclusive Group Adds Mellanox to BigTec Portfolio
DUCO19.10.2017 09:03 | pressemeddelelse
More Firms Select Duco for Mandatory MiFID II Reconciliation
SIAE-MICROELETTRONICA19.10.2017 09:02 | pressemeddelelse
SIAE MICROELETTRONICA Successfully Tests The SDN Application iVeritas in Telefónica Deutschland’s SDN Live Wireless Network
NV-RIMINI-STREET,-INC.19.10.2017 00:02 | pressemeddelelse
Rimini Street Expands Investment and Operations in Europe
CA-GILEAD-SCIENCES18.10.2017 23:45 | pressemeddelelse
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
NY-IFF18.10.2017 22:18 | pressemeddelelse
IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum